Regulus Therapeutics’ (RGLS) Market Perform Rating Reiterated at Leerink Partners
Leerink Partners restated their market perform rating on shares of Regulus Therapeutics (NASDAQ:RGLS – Free Report) in a report issued on Wednesday morning,Benzinga reports. The firm currently has a $7.00 price objective on the biopharmaceutical company’s stock. Several other equities research analysts have also commented on RGLS. HC Wainwright restated a “buy” rating and issued […]
Leerink Partners restated their market perform rating on shares of Regulus Therapeutics (NASDAQ:RGLS – Free Report) in a report issued on Wednesday morning,Benzinga reports. The firm currently has a $7.00 price objective on the biopharmaceutical company’s stock. Several other equities research analysts have also commented on RGLS. HC Wainwright restated a “buy” rating and issued […]
